PharmacyCodes



Quinaglute Dura-Tabs en es it fr

Categoria

Quinaglute Dura-Tabs Nombres de marca, Quinaglute Dura-Tabs Analogos

Quinaglute Dura-Tabs Marca los nombres de mezcla

  • No information avaliable

    • Quinaglute Dura-Tabs Formula quimica

    C20H24N2O2

    Quinaglute Dura-Tabs RX enlace

    http://www.rxlist.com/cgi/generic/quinidine.htm

    Quinaglute Dura-Tabs FDA hoja

    Quinaglute_Dura-Tabs FDA

    Quinaglute Dura-Tabs MSDS (hoja de seguridad de materiales)

    Quinaglute Dura-Tabs Sintesis de referencia

    No hay información disponible

    Quinaglute Dura-Tabs Peso molecular

    324.417 g/mol

    Quinaglute Dura-Tabs Punto de fusion

    174 oC

    Quinaglute Dura-Tabs H2O Solubilidad

    140 mg / L

    Quinaglute Dura-Tabs Estado

    Solid

    Quinaglute Dura-Tabs LogP

    2.534

    Quinaglute Dura-Tabs Formas de dosificacion

    Solución

    Quinaglute Dura-Tabs Indicacion

    Para el tratamiento de pre-excitación ventricular y arritmias cardíacas

    Quinaglute Dura-Tabs Farmacologia

    Quinidina, un anticonvulsivo fenitoína, se usa solo o junto con fenobarbital u otros anticonvulsivos para gestionar crisis tónico-clónicas, ataques psicomotores, los síndromes de dolor neuropático diabético incluyendo neuropatía, inducidas por digitálicos arritmias cardíacas y arritmias cardíacas asociadas con prolongación del intervalo QT.

    Quinaglute Dura-Tabs Absorcion

    No hay información disponible

    Quinaglute Dura-Tabs Toxicidad

    No hay información disponible

    Quinaglute Dura-Tabs Informacion de Pacientes

    Before prescribing QUINAGLUTE® as prophylaxis against recurrence of atrial fibrillation, the physician should inform the patient of the risks and benefits to be expected. Discussion should include the facts

    • that the goal of therapy will be a reduction (probably not to zero) in the frequency of episodes of atrial fibrillation; and
    • that reduced frequency of fibrillatory episodes may be expected, if achieved, to bring symptomatic benefit; but
    • that no data are available to show that reduced frequency of fibrillatory episodes will reduce the risks of irreversible harm through stroke or death; and in fact
    • that such data as are available suggest that treatment with QUINAGLUTE® is likely to increase the patient's risk of death.

    To confirm whether this is the most current prescribing information available on Quinaglute®, or to obtain the most current prescribing information, please call Berlex Laboratories at 1-888-BERLEX-4 (choose option #4, Product Usage Information).

    Quinaglute Dura-Tabs Organismos afectados

    Humanos y otros mamíferos